Story perspectives

Eli Lilly Invests $6B in Alabama Drug Manufacturing Facility

12/10/2025

Summary

Story summary

Eli Lilly and Company (the pharmaceutical company) announced plans to invest over $6 billion to build a manufacturing facility in Huntsville, Alabama, for active pharmaceutical ingredients, including the oral GLP-1 drug orforglipron, part of strengthening U.S. supply chains.
Construction will begin in 2026, with about 3,000 jobs and completion in 2032.
The site was chosen from more than 300 applicants due to its proximity to the HudsonAlpha Institute for Biotechnology.

1 of 1

Story summary

Eli Lilly and Company (the pharmaceutical company) announced plans to invest over $6 billion to build a manufacturing facility in Huntsville, Alabama, for active pharmaceutical ingredients, including the oral GLP-1 drug orforglipron, part of strengthening U.S. supply chains.
Construction will begin in 2026, with about 3,000 jobs and completion in 2032.
The site was chosen from more than 300 applicants due to its proximity to the HudsonAlpha Institute for Biotechnology.